Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.

[1]  Jing Zhang,et al.  Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects. , 2018, Clinical therapeutics.

[2]  I. Gould,et al.  Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen. , 2017, Journal of global antimicrobial resistance.

[3]  P. Eckburg,et al.  Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects , 2017, Antimicrobial Agents and Chemotherapy.

[4]  S. Wilson,et al.  Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Y. Xu,et al.  Dose Proportionality and Pharmacokinetics of Eplerenone in Healthy Chinese Subjects , 2015, Drug Research.

[6]  C. Crank,et al.  Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management , 2015, Infection and Drug Resistance.

[7]  Alicia Rodríguez-Gascón,et al.  Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[8]  Zhengyu Yuan,et al.  Metabolism of MRX-I, a Novel Antibacterial Oxazolidinone, in Humans: The Oxidative Ring Opening of 2,3-Dihydropyridin-4-One Catalyzed by Non-P450 Enzymes , 2015, Drug Metabolism and Disposition.

[9]  Zhengyu Yuan,et al.  New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. , 2014, Journal of medicinal chemistry.

[10]  Congran Li,et al.  In Vivo Antibacterial Activity of MRX-I, a New Oxazolidinone , 2014, Antimicrobial Agents and Chemotherapy.

[11]  M. Otto.  MRSA virulence and spread , 2012, Cellular microbiology.

[12]  G. Ippolito,et al.  Methicillin-resistant Staphylococcus aureus: the superbug. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  M. Falagas,et al.  Update on the safety of linezolid , 2009, Expert opinion on drug safety.

[14]  R. Moellering,et al.  Linezolid: The First Oxazolidinone Antimicrobial , 2002, Annals of Internal Medicine.

[15]  L. Squassante,et al.  Dose Linearity of Lacidipine Pharmacokinetics After Single and Repeated Oral Doses in Healthy Volunteers , 2003, Clinical pharmacokinetics.

[16]  James R. Johnson.  Linezolid: The First Oxazolidinone Antimicrobial , 2003, Annals of Internal Medicine.

[17]  Robert E. Johnson,et al.  From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, JAMA.

[18]  G. Moran,et al.  Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, MMWR. Morbidity and mortality weekly report.

[19]  F. Lowy.  Staphylococcus aureus infections. , 2009, The New England journal of medicine.

[20]  Eriksen Kr.  ["Celbenin"-resistant staphylococci]. , 1961 .

[21]  K. Eriksen,et al.  “Celbenin”-resistant Staphylococci , 1961, Ugeskrift for laeger.